Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Developmental and Epileptic Encephalopathies (DEEs) are severe childhood neurological disorders with refractory seizures and developmental impairments.
• Current treatments often fail to address the underlying genetic and molecular mechanisms of DEEs.

Purpose of the Study:

• To review the evolving landscape of precision therapeutics for DEEs.
• To focus on mechanism-driven interventions across key pathophysiologic categories.

Main Methods:

• Review of targeted therapies for channelopathies (e.g., antisense oligonucleotides, gene therapies for SCN1A-related Dravet syndrome).
• Exploration of treatments for neurotransmitter receptor and synaptic dysfunctions.
• Examination of precision interventions for cellular signaling, epigenetic regulation, and metabolic pathways.

Main Results:

• Specific examples of precision therapeutics include zorevunersen, ETX101, gaboxadol, radiprodil, l-serine, chemical chaperones, and MEK inhibitors.
• The review highlights advances in treating DEEs by targeting specific genetic and molecular pathways.
• Emphasis on the importance of genetic testing, natural history studies, and innovative clinical trial designs.

Conclusions:

• Precision therapeutics hold significant promise for improving outcomes in DEEs through tailored, equitable, and patient-centered care.
• Future directions involve overcoming gene-based therapy challenges, integrating systems biology, and leveraging AI.
• Collaboration among stakeholders is crucial for advancing DEE treatment.